Antimicrobial Susceptibility and Synergy Studies of Stenotrophomonas maltophilia Isolates from Patients with Cystic Fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 168-171

  San Gabriel, Pablo ^a   Zhou, Juyan ^a   Tabibi, Setareh ^a   Chen, Yunhua ^a   Trauzzi, Marco ^a   Saiman, Lisa ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; PIPERACILLIN; TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; CYSTIC FIBROSIS; DILUTION; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; STENOTROPHOMONAS MALTOPHILIA;

EID: 0347361712     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.168-171.2004     Document Type: Article

References (41)

1. Alonso, A., P. Sanchez, and J. L. Martinez. 2000. Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance. Antimicrob. Agents Chemother. 44:1778-1782.
2. Beringer, P. 2001. The clinical use of colistin in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 7:434-440.
3. Burdge, D. R., M. A. Noble, M. E. Campbell, V. L. Krell, and D. P. Speert. 1995. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin. Infect. Dis, 20:445-448.
4. Burns, J. L., J. Emerson, J. R. Stapp, D. L. Yim, J. Krzewinski, L. Louden, B. W. Ramsey, and C. R. Clausen. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:158-163.
5. Burns, J. L., and L. Saiman. 1999. Burkholderia cepacia infections in cystic fibrosis. Pediatr. Infect. Dis. J. 18:155-156.
6. Burns, J. L., J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. 1999. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179:1190-1196.
7. Campbell, P. W., and L. Saiman. 1999. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 116:775-788.
8. Cullmann, W. 1991. Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. Chemotherapy 37:246-250.
9. Cystic Fibrosis Foundation. 1997. Patient registry 1996. p. 1-51. Annual report. Cystic Fibrosis Foundation. Bethesda, Md.
10. Cystic Fibrosis Foundation. 1998. Patient registry 1997, p. 1-55. Annual report. Cystic Fibrosis Foundation, Bethesda, Md.
11. Cystic Fibrosis Foundation. 1999. Patient registry 1998, p. 1-21. Annual report. Cystic Fibrosis Foundation, Bethesda, Md.
12. Cystic Fibrosis Foundation. 2000. Patient registry 1999. p. 1-21. Annual report. Cystic Fibrosis Foundation, Bethesda, Md.
13. Cystic Fibrosis Foundation. 2001. Patient registry 2000, p. 1-24. Annual report. Cystic Fibrosis Foundation. Bethesda, Md.
14. Cystic Fibrosis Foundation. 2002. Patient registry 2001. p. 1-28. Annual report. Cystic Fibrosis Foundation, Bethesda, Md.
15. Elion, G. B., S. Singer, and G. H. Hitchings. 1954. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208:477-488.
16. Eliopoulos, G. M., and R. C. Moellering. 1991. Antibiotic combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, Md.
17. FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr. 122:1-9.
18. Garrod, L. P., and P. M. Waterworth. 1962. Methods of testing combined antibiotic bactericidal action and the significance of the results. J. Clin. Pathol. 15:328-338.
19. Gilbert, D. N., R. C. Moellering, and M. A. Sande (ed.). 2003. The Sanford guide to antimicrobial therapy, 33rd ed., p. 50, 52-54. Antimicrobial Therapy, Inc., Hyde Park, Vt.
20. Igari, J., N. Kosakai, and T. Oguri. 1982. Susceptibilities of Pseudomonas species to aminoglycosides and tetracyclines. Jpn. J. Antibiot. 35:1233-1239.
21. Jacobs, D. S., W. R. D. Mott, and D. K. Oxley. 2001. Jacobs & DeMott laboratory test handbook with key word index, 5th ed. Lexi Comp, Hudson, Ohio.
22. Kerem, B., J. M. Rommens, J. A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, M. Buchwald, and L. C. Tsui. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-1080.
23. Klinger, J. D., and M. J. Thomassen. 1985. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 3:149-158.
24. Mendelman, P. M., A. L. Smith, J. Levy, A. Weber, B. Ramsey, and R. L. Davis. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. J. Respir. Crit. Care Med. 132:761-765.
25. Mett, H., S. Rosta, B. Schacher, and R. Frei. 1998. Outer membrane permeability and beta-lactamase content in Pseudomonas maltophilia clinical isolates and laboratory mutants. Rev. Infect. Dis. 10:765-769.
26. Moss, R. B. 1995. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin. Infect. Dis. 21:839-849.
27. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. NCCLS document M100-S12, p. 43-44. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Olivier, K. N., D. J. Weber, J. H. Lee, A. Handler, G. Tudor, P. L. Molina, J. Tomashefski, and M. R. Knowles. 2003. Nontuberculous mycobacteria. II. Nested-cohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167:835-840.
29. Olivier, K. N., D. J. Weber, R. J. Wallace, A. R. Faiz, J. H. Lee, Y. Zhang, B. A. Brown Elliot, A. Handler, R. W. Wilson, M. S. Schechter, L. J. Edwards, S. Chakraborti, and M. R. Knowles. 2003. Nontuberculous mycobacteria. I. Multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med. 167:828-834.
30. Ramsey, B. W. 1996. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 335:179-188.
31. Ramsey, B. W., M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, M. Vasiljev-K, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, and A. L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 340:23-30.
32. Sahm, D. F., I. A. Critchley, L. J. Kelly, J. A. Karlowsky, D. C. Mayfield, C. Thornsberry, Y. R. Mauriz, and J. Kahn. 2001. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob. Agents Chemother. 45:267-274.
33. Saiman, L., J. L. Burns, S. Whittier, J. Krzewinski, S. A. Marshall, and R. N. Jones. 1999. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J. Clin. Microbiol. 37:2987-2991.
34. Saiman, L., Y. Chen, P. S. Gabriel, and C. Knirsch. 2002. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46:1105-1107.
35. Saiman, L., Y. Chen, S. Tabibi, P. San Gabriel, J. Zhou, Z. Liu, L. Lai, and S. Whittier. 2001. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39:3942-3945.
36. Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537.
37. Saiman, L., J. Siegel, and the Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. 2003. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect. Control Hosp. Epidemiol. 24:1-52.
38. Saino, Y., M. Inoue, and S. Mitsuhashi. 1984. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob. Agents Chemother. 25:362-365.
39. Saino, Y., F. Kobayashi, M. Inoue, and S. Mitsuhashi. 1982. Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob. Agents Chemother. 22:564-570.
40. Vartivarian, S., E. Anaissie, G. Bodey, H. Sprigg, and K. Rolston. 1994. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob. Agents Chemother. 38:624-627.
41. Zhang, L., X. Z. Li, and K. Poole. 2000. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob. Agents Chemother. 44:287-293.